Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Asset disposition
Wright Medical Group N.V. (WMGI) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/07/2019 8-K Quarterly results
Docs: "Wright Medical Group N.V. Reports 2019 Second Quarter Financial Results Second Quarter 2019 Net Sales, Including Cartiva ® , of $230 Million, Representing As-Reported Growth of 12%, Constant Currency Growth of 13% and Organic Constant Currency Growth of 9% Second Quarter 2019 Net Loss From Continuing Operations of $19 Million; Non-GAAP Adjusted EBITDA From Continuing Operations of $35 Million, Representing Non-GAAP Adjusted EBITDA Margin of 15%, an Approximate 290 Basis Point Expansion Over Prior Year Quarter Company Updates 2019 Annual Guidance Reiterates Long-Term Financial Targets of Double-Digit Constant Currency Net Sales Growth, Gross Margins in High 70s% Range and Non-GAAP Adjusted EBITDA Margin of Mid-20% Range Exiting 2021"
05/07/2019 8-K Quarterly results
Docs: "Wright Medical Group N.V. Reports 2019 First Quarter Financial Results First Quarter 2019 Net Sales, Including Cartiva ® , of $230 Million, Representing As-Reported Growth of 16%, Constant Currency Growth of 18% and Organic Constant Currency Growth of 13% First Quarter 2019 Record Gross Margins of 80% First Quarter 2019 Net Loss From Continuing Operations of $30 Million; Non-GAAP Adjusted EBITDA From Continuing Operations of $37 Million, Representing Non-GAAP Adjusted EBITDA Margin of 16%, an Approximate 300 Basis Point Expansion Over Prior Year Quarter Company Reiterates 2019 Annual Guidance"
02/26/2019 8-K Quarterly results
08/08/2018 8-K Quarterly results
Docs: "Wright Medical Group N.V. Reports 2018 Second Quarter Financial Results Second Quarter 2018 Net Sales of $205 Million Second Quarter 2018 Net Loss From Continuing Operations of $91 Million; Non-GAAP Adjusted EBITDA From Continuing Operations of $26 Million U.S. Upper Extremities Business Increased 22%, Led by Sales Growth of SIMPLICITI™ Shoulder System U.S. Lower Extremities Business Growth Rate Accelerates to 9%; AUGMENT ® Injectable Approved in U.S. Company Increases 2018 Annual Guidance"
05/09/2018 8-K Quarterly results
Docs: "Wright Medical Group N.V. Reports 2018 First Quarter Financial Results First Quarter 2018 Net Sales of $199 Million First Quarter 2018 Net Loss From Continuing Operations of $20 Million; Non-GAAP Adjusted EBITDA From Continuing Operations of $27 Million U.S. Upper Extremities Business Increased 21%, Led by Ongoing Launch of PERFORM™ Reversed Glenoid U.S. Lower Extremities Business Growth Rate Accelerates to 2.5% Resolution of U.K. Insurance Dispute Results in $30.75 Million Recovery Company Reaffirms Previously Provided 2018 Annual Guidance"
02/27/2018 8-K Quarterly results
Docs: "Wright Medical Group N.V. Reports 2017 Fourth Quarter and Full-Year Financial Results and Provides 2018 Annual Guidance Fourth Quarter 2017 Net Sales of $218 Million; Full-Year 2017 Net Sales of $745 Million Fourth Quarter 2017 Net Income From Continuing Operations of $27 Million; Non-GAAP Adjusted EBITDA From Continuing Operations of $38 Million Full-Year 2017 Net Loss from Continuing Operations of Negative $65 Million; Non-GAAP Adjusted EBITDA From Continuing Operations of Positive $88 Million U.S. Upper Extremities Business Increased 29%, Led by Ongoing Launch of PERFORM™ Reversed Glenoid Company Provides Full-Year 2018 Net Sales Guidance of $800 Million to $812 Million Company Provides Full-Year 2018 Non-GAAP Adjusted EBITDA Guidance of $104 Million to $111 Million"
11/01/2017 8-K Quarterly results
Docs: "Wright Medical Group N.V. Reports 2017 Third Quarter Financial Results and Updated 2017 Annual Guidance Third Quarter 2017 Net Sales of $170.5 Million Third Quarter 2017 Net Loss From Continuing Operations of $34 Million; Non-GAAP Adjusted EBITDA From Continuing Operations of Positive $12 Million U.S. Upper Extremities Business Increased 19%, Led by Ongoing Launch of PERFORM™ Reversed Glenoid Company Updates Previously Provided Full-Year 2017 Net Sales Guidance to $740 Million to $745 Million Company Increases Full-Year 2017 Non-GAAP Adjusted EBITDA Guidance to $84 Million to $88 Million"
08/02/2017 8-K Quarterly results
05/03/2017 8-K Form 8-K - Current report
02/21/2017 8-K Quarterly results
Docs: "Wright Medical Group N.V. Reports 2016 Fourth Quarter and Full-Year Financial Results and Provides 2017 Guidance Full-Year 2016 Net Sales of $690 Million As Reported Exceeds High-End Of Company’s Previously Provided 2016 Guidance Range Fourth Quarter 2016 Net Sales From Continuing Operations of $193 Million As Reported Fourth Quarter 2016 Net Loss From Continuing Operations of $30 Million; Non-GAAP Adjusted EBITDA From Continuing Operations of Positive $23 Million Company Provides Full-Year 2017 Net Sales Guidance of $755 Million to $765 Million"
11/02/2016 8-K Form 8-K - Current report
08/02/2016 8-K Form 8-K - Current report
05/04/2016 8-K Form 8-K - Current report
02/23/2016 8-K Quarterly results
Docs: "Wright Medical Group N.V. Reports 2015 Fourth Quarter and Full-Year Financial Results and Provides 2016 Guidance Fourth Quarter 2015 Net Sales of $177 Million As Reported; $181 Million Pro-Forma Full-Year 2015 Net Sales of $415 Million As Reported; Pro-Forma Full-Year 2015 Net Sales of $656 Million Exceeds High-End Of Company’s Previously Provided 2015 Guidance Range Company Provides Full-Year 2016 Net Sales Guidance of $695 Million to $705 Million"
11/04/2015 8-K Quarterly results
Docs: "Wright Medical Group N.V. Reports 2015 Third Quarter Financial Results Third Quarter Legacy Wright Global Foot and Ankle Net Sales Increase 20% As Reported and 23% Constant Currency Third Quarter Legacy Wright Global Total Ankle Replacement Sales Increase 61% As Reported Third Quarter Legacy Tornier Global Upper Extremity Revenue Increases 7% As Reported and 13% Constant Currency Provides Pro Forma Guidance for 2015 for Combined Company Following Merger with Tornier N.V."
08/05/2015 8-K Quarterly results
Docs: "Tornier Reports Second Quarter 2015 Results"
05/05/2015 8-K Quarterly results
Docs: "Tornier Reports First Quarter 2015 Results And Provides Updated 2015 Outlook"
11/06/2014 8-K Quarterly results
Docs: "Tornier Reports Third Quarter 2014 Results"
08/07/2014 8-K Quarterly results
Docs: "Tornier Reports Second Quarter 2014 Results"
05/06/2014 8-K Quarterly results
Docs: "Tornier Reports First Quarter 2014 Results"
11/05/2013 8-K Form 8-K - Current report
08/06/2013 8-K Form 8-K - Current report
05/07/2013 8-K Form 8-K - Current report
11/05/2012 8-K Form 8-K - Current report
08/07/2012 8-K Form 8-K - Current report
05/08/2012 8-K Form 8-K - Current report
02/23/2012 8-K Form 8-K - Current report
01/09/2012 8-K Form 8-K - Current report
11/08/2011 8-K Form 8-K - Current report
08/09/2011 8-K Form 8-K - Current report
05/09/2011 8-K Form 8-K - Current report

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy